Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 270

1.

Insulin lispro improves postprandial glucose control in patients with diabetes mellitus.

Skrha J, Smahelová A, Andĕl M, Vrtovec M, Subić J, Kreze A, Vozar J, Korecová M, de Verga V, Wyatt J, Metcalfe S, Ristić S.

Sb Lek. 2002;103(1):15-21.

PMID:
12448933
2.

Treatment of type 1 diabetes with insulin lispro during Ramadan.

Kadiri A, Al-Nakhi A, El-Ghazali S, Jabbar A, Al Arouj M, Akram J, Wyatt J, Assem A, Ristic S.

Diabetes Metab. 2001 Sep;27(4 Pt 1):482-6.

PMID:
11547222
3.

Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents.

Holcombe JH, Zalani S, Arora VK, Mast CJ; Lispro in Adolescents Study Group.

Clin Ther. 2002 Apr;24(4):629-38.

PMID:
12017407
4.

Insulin lispro lowers postprandial glucose in prepubertal children with diabetes.

Deeb LC, Holcombe JH, Brunelle R, Zalani S, Brink S, Jenner M, Kitson H, Perlman K, Spencer M.

Pediatrics. 2001 Nov;108(5):1175-9.

PMID:
11694699
5.

Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.

Anderson JH Jr, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R.

Arch Intern Med. 1997 Jun 9;157(11):1249-55.

PMID:
9183237
6.
7.

Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.

Malone JK, Woodworth JR, Arora V, Yang H, Campaigne BN, Hallé JP, Yale JF, Grossman LD.

Clin Ther. 2000 Feb;22(2):222-30.

PMID:
10743981
10.

Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.

Renner R, Pfützner A, Trautmann M, Harzer O, Sauter K, Landgraf R.

Diabetes Care. 1999 May;22(5):784-8.

11.

Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.

Feinglos MN, Thacker CH, English J, Bethel MA, Lane JD.

Diabetes Care. 1997 Oct;20(10):1539-42.

PMID:
9314631
12.

Insulin lispro in CSII: results of a double-blind crossover study.

Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T.

Diabetes. 1997 Mar;46(3):440-3. Erratum in: Diabetes 1997 Jul;46(7):1239.

PMID:
9032100
13.

Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial.

Annuzzi G, Del Prato S, Arcari R, Bellomo Damato A, Benzi L, Bruttomesso D, Calderini MC, Coscelli C, Fedele D, Galluzzo A, Giordano M, Giorgino R, Lapolla A, Orsini P, Pagano G, Santoro D, Riccardi G.

Nutr Metab Cardiovasc Dis. 2001 Jun;11(3):168-75.

PMID:
11590992
15.
16.

Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes.

Pfützner A, Küstner E, Forst T, Schulze-Schleppinghoff B, Trautmann ME, Haslbeck M, Schatz H, Beyer J.

Exp Clin Endocrinol Diabetes. 1996;104(1):25-30.

PMID:
8750567
18.

Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group.

Anderson JH Jr, Brunelle RL, Koivisto VA, Pfützner A, Trautmann ME, Vignati L, DiMarchi R.

Diabetes. 1997 Feb;46(2):265-70.

PMID:
9000704
19.
20.

Optimal provision of daytime NPH insulin in patients using the insulin analog lispro.

Ahmed AB, Home PD.

Diabetes Care. 1998 Oct;21(10):1707-13.

PMID:
9773735

Supplemental Content

Support Center